EUSA Pharma (UK) Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EUSA Pharma (UK) Ltd.
China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.
Recordati Expands Into Rare Cancer Space With EUSA Pharma Buy
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.
Emerging Biopharma’s Next First Launch Market: China?
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.
Keeping Track: US FDA Approval Of Jazz Rylaze Addresses Shortage; MediWound, Cyclopharm Receive CRLs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Medical Devices
- Specialty Pharmaceuticals
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.